Vitamin D and Osteoclastogenesis

Vitamin D

Volumn 1, Issue , 2005, Pages 665-685

  Yasuda, Hisataka ^a   Higashio, Kanji ^b   Suda, Tatsuo ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34347341433     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012252687-9/50041-3     Document Type: Chapter

References (114)

1. DeLuca HF The vitamin d story: a collaborative effort of basic science and clinical medicine. FASEB J 1988, 2:224-236.
2. Reichel H, Koeffler HP, Norman AW The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989, 320:980-991.
3. Suda T, Ueno Y, Fujii K, Shinki T Vitamin D and bone. J Cell Biochem 2003, 88:259-266.
4. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T, Kato S Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997, 16:391-396.
5. Carlsson A Tracer experiments on the effects of vitamin D on the skeletal metabolism of calcium and phosphorus. Acta Physiol Scan 1952, 26:212-220.
6. Raisz LG, Trummel CL, Holick MF, DeLuca HF 1,25-Dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science 1972, 175:768-769.
7. 3. Proc Natl Acad Sci USA 1981, 78:4990-4994.
8. Tanaka H, Abe E, Miyaura C, Kuribayashi T, Konno K, Nishii Y, Suda T 1α,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem J 1982, 204:713-719.
9. 3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. Proc Natl Acad Sci USA 1983, 80:5583-5587.
10. Rodan GA, Martin TJ Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif Tissue Int 1981, 33:349-351.
11. Chambers TJ Regulation of osteoclast development and function. Biology and Physiology of the Osteoclast 1992, 105-128. CRC Press, Boca Raton, FL. B.R. Rifkin, C.V. Gay (Eds.).
12. 3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells. Endocrinology 1988, 123:1504-1510.
13. Suda T, Takahashi N, Martin TJ Modulation of osteoclast differentiation. Endocr Rev 1992, 13:66-80.
14. Chambers TJ, Owens JM, Hattersley G, Jat PS, Noble MD Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA 58 transgenic mouse. Proc Natl Acad Sci USA 1993, 90:5578-5582.
15. Takahashi N, Udagawa N, Akatsu T, Tanaka H, Isogai Y, Suda T Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology 1991, 128:1792-1796.
16. Tamaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T Macrophage colonystimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993, 91:257-263.
17. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
18. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N Modulation of osteoclast differentiation by local factors. Bone 1995, 17:87S-91S.
19. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997, 234:137-142.
20. Higashio K, Shima N, Goto M, Itagaki Y, Nagao M, Yasuda H, Morinaga T Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. Biochem Biophys Res Commun 1990, 170:397-404.
21. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
22. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
23. Riggs BL, Baron R, Boyle WJ, Drezner M, Manolagas S, Martin TJ, Stewart AF, Suda T, Yasuda H, Aubin J, Goltzman D Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. J Bone Miner Res 2000, 15:2293-2296.
24. Riggs BL, Baron R, Boyle WJ, Drezner M, Manolagas S, Martin TJ, Stewart AF, Suda T, Yasuda H, Aubin J, Goltzman D Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. Bone 2000, 27:761-764.
25. Tomoyasu A, Goto M, Fujise N, Mochizuki S, Yasuda H, Morinaga T, Tsuda E, Higashio K Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun 1998, 245:382-387.
26. Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998, 23:495-498.
27. Yamamoto M, Murakami T, Nishikawa M, Tsuda E, Mochizuki S, Higashio K, Akatsu T, Motoyoshi K, Nagata N Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 1998, 139:4012-4015.
28. Capparelli C, Kostenuik PJ, Monory S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000, 60:783-787.
29. 3. J Bone Miner Res 1999, 14:1478-1485.
30. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432-4436.
31. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000, 6:521-528.
32. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001, 98:3534-3540.
33. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
34. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998, 247:610-615.
35. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002, 347:175-184.
36. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002, 11:2119-2127.
37. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in post-menopausal women with osteoporosis. J Bone Miner Res 1999, 14:518-527.
38. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998, 273:5117-5123.
39. Morinaga T, Nakagawa N, Yasuda H, Tsuda E, Higashio K Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur J Biochem 1998, 254:685-691.
40. Mizuno A, Murakami A, Nakagawa N, Yasuda H, Tsuda E, Morinaga T, Higashio K Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. Gene 1998, 215:339-343.
41. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, Martin TJ, Suda T The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989, 125:1805-1813.
42. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
43. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
44. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
45. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
46. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990, 87:7260-7264.
47. Miyamoto A, Kunisada T, Hemmi H, Yamane T, Yasuda H, Miyake K, Yamazaki H, Hayashi SI Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochem Biophys Res Commun 1998, 242:703-709.
48. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Morinaga T, Toyama Y, Yabe Y, Higashio K, Suda T Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998, 246:199-204.
49. Quinn JM, Elliott J, Gillespie MT, Martin TJ A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139:4424-4427.
50. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
51. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999, 25:109-113.
52. 2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 1998, 246:337-341.
53. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999, 145:527-538.
54. Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, Kinosaki M, Yamaguchi K, Tsuda E, Murakami A, Yasuda H, Higashio K Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 2002, 20:337-344.
55. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
56. Kim N, Odgren PR, Kim DK, Marks SC, Choi Y Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000, 97:10905-10910.
57. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998, 253:395-400.
58. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
59. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
60. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostemuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97:1566-1571.
61. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM Mutation in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Gene 2000, 24:45-48.
62. Whyte MP, Hughes AE Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002, 17:26-29.
63. Kobayashi K, Takanashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286.
64. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000, 275:4858-4864.
65. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL TNFα induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488.
66. Murakami T, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K, Akatsu T Transforming growth factorβ1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 1998, 252:747-752.
67. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitor factor by bone marrow stromal cells. J Biol Chem 1998, 273:27091-27096.
68. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 2001, 16:1787-1794.
69. Udagawa N, Takahashi N, Yasuda H, Mizumo A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000, 141:3478-3484.
70. Horwood NJ, Elliott J, Martin TJ, Gillespie MT Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998, 139:4743-4746.
71. Lee SK, Lorenzo JA Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999, 140:3552-3561.
72. 2 in human bone marrow stroma cells. Biochem Biophys Res Commun 1998, 247:338-341.
73. 3 or parathyroid hormone. J Biol Chem 1999, 274:19301-19308.
74. Vidal NO, Brandstrom H, Jonsson KB, Ohlsson C Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 1998, 159:191-195.
75. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382-4389.
76. Hofbauer LC, Khosla S, Dunstan CR, Lancey DL, Spelsberg TC, Riggs BL Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
77. Vidal ON, Sjogren K, Eriksson BI, Ljunggren O, Ohlsson C Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 1998, 248:696-700.
78. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S Interleukin-1β and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25:255-259.
79. Brandstrom H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren O Tumor necrosis factor-alpha and-beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 1998, 248:454-457.
80. Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo JT, Martin TJ, Nagai K, Suda T Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factorκB ligand and osteoprotegerin in osteoblasts. Endocrinology 2000, 141:4711-4719.
81. Nakagawa N, Yasuda H, Yano K, Mochizuki S, Kobayashi N, Fujimoto H, Shima N, Morinaga T, Chikazu D, Kawaguchi H, Higashio K Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Biochem Biophys Res Commun 1999, 265:158-163.
82. 3 through suppressing the production of osteoclast differentiation factor. Biochem Biophys Res Commun 1999, 265:45-50.
83. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998, 250:776-781.
84. Koide M, Murase Y, Yamato K, Noguchi T, Okahashi N, Nishihara T Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1α, through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Biophys Res Commun 1999, 259:97-102.
85. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16:348-360.
86. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97:887-892.
87. Peterson MC, Stouch BJ, Chen D, Baughman S, DA M., Dunstan CR, Martin SW AMG 162, a fully human monoclonal antibody against receptor activator of NFκB ligand (RANKL), rapidly and profoundly suppresses bone resorption in cynomolgus monkey. Bone 2003, 32(Suppl 1):S44.
88. Louie SG, Park B, Yoon H Biological response modifiers in the management of rheumatoid arthritis. Am J Health Syst Pharm 2003, 60:346-355.
89. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NFκB, a member of the TNFR superfamily. J Biol Chem 1998, 273:34120-34127.
90. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB Characterization of the intracellular domain of receptor activator of NFκB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NFκB and c-Jun N-terminal kinase. J Biol Chem 1998, 273:20551-20555.
91. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J Severe osteopetrosis, defective interleukin-1 signaling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999, 4:353-362.
92. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999, 13:1015-1024.
93. Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 2001, 20:1271-1280.
94. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605.
95. Kaji K, Katogi R, Azuma Y, Naito A, Inoue JI, Kudo A Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Miner Res 2001, 16:1593-1599.
96. Soriano P, Montgomery C, Geske R, Bradley A Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64:693-702.
97. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999, 4:1041-1049.
98. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF Bone and haematopoietic defects in mice lacking c-fos. Nature 1992, 360:741-745.
99. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
100. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000, 24:184-187.
101. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416:744-749.
102. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J Cell Sci 2002, 115:4317-4325.
103. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NFκB ligand (RANKL). J Biol Chem 2000, 275:31155-31161.
104. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, Suda T, Takahashi N p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002, 143:3105-3113.
105. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U Requirement for NFκB in osteoclast and B-cell development. Genes Dev 1997, 11:3482-3496.
106. Iotsova V, Caamano J, Loy L, Yang Y, Lewin A, Bravo R Osteopetrosis in mice lacking NFκB1 and NFκB2. Nat Med 1997, 3:1285-1289.
107. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999, 163:434-442.
108. Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R, Teitelbaum SL Osteopetosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997, 386:81-84.
109. Luchin A, Purdom G, Murphy K, Clark MY, Angel N, Cassady AI, Hume DA, Ostrowski MC The microphthamia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. J Bone Miner Res 2000, 15:451-460.
110. Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ, Fisher DE Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci USA 2001, 98:5798-5803.
111. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002, 277:41147-41156.
112. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Tamiguchi T Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
113. Suda T, DeLuca HF, Tanaka Y Biological activity of 25-hydroxyergocalciferol in rats. J Nutr 1970, 100:1049-1052.
114. 3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem 2003, 90:267-277.